Back to top
more

CareDx (CDNA)

(Delayed Data from NSDQ)

$8.31 USD

8.31
499,413

+0.24 (2.97%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $8.32 +0.01 (0.12%) 4:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CDNA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

CareDx, Inc. [CDNA]

Reports for Purchase

Showing records 41 - 60 ( 80 total )

Company: CareDx, Inc.

Industry: Medical Services

Record: 41

06/01/2020

Company Report

Pages: 5

Transplant Volume Exhibits V-Shaped Recovery; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 42

05/18/2020

Company Report

Pages: 5

AlloSeq Transplant Matching Test Obtains CE Mark; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 43

05/15/2020

Company Report

Pages: 6

Veracyte Partnership Inked for Transplant Rejection Testing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 44

05/06/2020

Company Report

Pages: 5

Urine-Based Surveillance Test Partnership Established; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 45

05/01/2020

Company Report

Pages: 6

1Q20 Financial Results Reported; Reiterate Buy; Modulating PT to $40

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 46

04/24/2020

Company Report

Pages: 5

AlloSure Lung Surveillance Launched; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 47

04/15/2020

Company Report

Pages: 5

Cell Therapy Surveillance Solution Unveiled; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 48

04/09/2020

Company Report

Pages: 5

Preliminary 1Q20 Results; 2020 Guidance Withdrawn; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 49

03/23/2020

Company Report

Pages: 5

AlloSure Application in Post-Immunotherapy Re-Transplantation Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 50

03/18/2020

Company Report

Pages: 5

Home-Based Transplant Patient Monitoring Solution Launched; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 51

02/28/2020

Company Report

Pages: 6

Full-Year 2019 Shows Impressive 66% Top-Line Growth; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 52

02/27/2020

Company Report

Pages: 5

AlloSure Utility to Differentiate Ambiguous Rejections Published; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 53

01/21/2020

Company Report

Pages: 6

2019 Preliminary Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 54

01/13/2020

Company Report

Pages: 6

AlloSeq cfDNA Kit Obtains CE Mark Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 55

11/05/2019

Company Report

Pages: 5

Improved AlloSure Test Launched, Facilitating More Personalized Transplant Patient Care

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 56

11/01/2019

Company Report

Pages: 6

Impressive 60% Top-Line Growth in 3Q19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 57

09/25/2019

Company Report

Pages: 6

Collaboration With NanoString Adds HistoMap Test; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 58

09/19/2019

Company Report

Pages: 6

Outcomes of KidneyCare in Renal Allografts Registry Enrolls First Patient; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 59

08/29/2019

Company Report

Pages: 6

Acquisition of XynManagement Completed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 60

08/23/2019

Company Report

Pages: 5

AlloSure-Heart Receives Positive Medicare Coverage Decision; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 10.00

Research Provided by a Third Party